Skip to main content Back to Top
Advertisement

5/22/2017

Ondansetron Injection

Products Affected - Description

    • Ondansetron injection, AuroMedics, 2 mg/mL, 20 mL vial, 1 count, NDC 55150-0126-20
    • Ondansetron injection, Heritage, 2 mg/mL, 2 mL vial, 10 count, NDC 23155-0196-42
    • Ondansetron injection, Heritage, 2 mg/mL, 20 mL vial, 1 count, NDC 23155-0168-31
    • Ondansetron injection, Teva, 2 mg/mL, 20 mL vial, 1 count, NDC 00703-7226-01
    • Ondansetron injection, Teva, 2 mg/mL, 20 mL vial, 10 count, NDC 00703-7226-03

Reason for the Shortage

    • AuroMedics did not provide a reason for the shortage.
    • Fresenius Kabi has ondansetron injection available.
    • Heritage has ondansetron injection available.
    • Mylan Institutional has ondansetron injection available.
    • Novartis has Zofran injection available.
    • Pfizer has ondansetron injection available.
    • Sagent has ondansetron injection available.
    • Teva discontinued ondansetron 2 mg/mL 20 mL vials. The 2 mL vials are available.
    • West-Ward has ondansetron injection available.
    • Wockhardt has ondansetron injection on an FDA import alert.

Available Products

    • Zofran injection, Novartis, 2 mg/mL, 20 mL vial, 1 count, NDC 00173-0442-00
    • Ondansetron injection, AuroMedics, 2 mg/mL, 2 mL vial, 25 count, NDC 55150-0125-02
    • Ondansetron injection, Fresenius Kabi, 2 mg/mL, 2 mL prefilled syringe, 24 count, NDC 76045-0103-20
    • Ondansetron injection, Fresenius Kabi, 2 mg/mL, 2 mL vial, 25 count, NDC 63323-0373-02
    • Ondansetron injection, Fresenius Kabi, 2 mg/mL, 20 mL vial, 1 count, NDC 63323-0374-20
    • Ondansetron injection, Heritage, 2 mg/mL, 2 mL vial, 10 count, NDC 23155-0547-41
    • Ondansetron injection, Heritage, 2 mg/mL, 2 mL vial, 25 count, NDC 23155-0547-42
    • Ondansetron injection, Heritage, 2 mg/mL, 20 mL vial, 1 count, NDC 23155-0549-31
    • Ondansetron injection, Mylan Institutional, 2 mg/mL, 2 mL vial, 25 count, NDC 67457-0441-20
    • Ondansetron injection, Mylan Institutional, 2 mg/mL, 20 mL vial, 1 count, NDC 67457-0440-20
    • Ondansetron injection, Pfizer, 2 mg/mL, 2 mL iSecure syringe, 10 count, NDC 00409-1120-12
    • Ondansetron injection, Pfizer, 2 mg/mL, 2 mL vial, 25 count, NDC 00409-4755-03
    • Ondansetron injection, Pfizer, 2 mg/mL, 20 mL vial, 1 count, NDC 00409-4759-01
    • Ondansetron injection, Sagent, 2 mg/mL, 2 mL vial, 25 count, NDC 25021-0777-02
    • Ondansetron injection, Teva, 2 mg/mL, 2 mL vial, 25 count, NDC 00703-7221-04
    • Ondansetron injection, West-Ward, 2 mg/mL, 2 mL vial, 25 count, NDC 00641-6078-25
    • Ondansetron injection, West-Ward, 2 mg/mL, 20 mL vial, 1 count, NDC 00143-9890-01
    • Ondansetron injection, West-Ward, 2 mg/mL, 20 mL vial, 1 count, NDC 00641-6079-01

Estimated Resupply Dates

    • AuroMedics has ondansetron 2 mg/mL 2 mL vials on intermittent back order and the company is releasing product as it becomes available.

Updated

Updated May 22, 2017 by Leslie Jensen, PharmD, Drug Information Specialist. Created January 23, 2009 by Michelle Wheeler, PharmD, Drug Information Specialist. Copyright 2017, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

This information is provided through the support of Vizient to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Vizient, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Vizient, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Vizient, ASHP nor University of Utah endorses or recommends the use of any drug.

« Back to Drug Shortage Product Bulletins